Application of lipid compound combination in T cell culture
A cell culture and compound technology, applied in cell culture active agents, animal cells, tissue culture, etc., can solve the problem of not considering the proportion of CD4 and CD8 subgroups, and achieve no animal-derived components, clear chemical components, high clinical The effect of applying value
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0043] Example 1 Expansion of different proportions of CD4-positive and CD8-positive T cells in human peripheral blood mononuclear cells (PBMC) (1)
[0044] In this example, PBMCs were freshly isolated from human whole blood by density centrifugation for activation and expansion of T cells. Transfer the separated PBMC cell suspension to the prepared 6-well culture dish, seeding density 1x10 6 / ml, use X-Vivo-15 (Lonza) medium 2mL / well added with lipid compound combination solution, and add CD3 antibody at a final concentration of 10μg / mL, CD28 antibody at a final concentration of 5μg / mL, and a final concentration of 100IU / mL IL2, and placed in a 37°C, 5% carbon dioxide incubator to continue culturing.
[0045]Wherein, the solute of lipid compound combination solution is following 8 kinds of lipids: myristic acid, arachidonic acid, cholesterol, linoleic acid, oleic acid, palmitic acid, hard fatty acid, linolenic acid; Its concentration is 0.00125g / L.
[0046] Four conditio...
Embodiment 2
[0048] Example 2 Expansion of different proportions of CD4-positive and CD8-positive T cells in human peripheral blood mononuclear cells (PBMC) (2)
[0049] In this example, PBMCs were freshly isolated from human whole blood by density centrifugation for activation and expansion of T cells. Transfer the separated PBMC cell suspension to the prepared 6-well culture dish, seeding density 1x10 6 / ml, use OpTmizer (ThermoFisher) medium 2mL / well added with lipid compound combination solution, and add CD3 antibody at a final concentration of 10 μg / mL, CD28 antibody at a final concentration of 5 μg / mL, and IL2 at a final concentration of 100 IU / mL , and placed in a 37°C, 5% carbon dioxide incubator to continue culturing.
[0050] Wherein, the solute of the lipid compound combination solution is the following two kinds of lipids: myristic acid and arachidonic acid; the concentrations thereof are both 0.00125 g / L.
[0051] Four conditions were set up in the experiment, and the additi...
Embodiment 3
[0053] Example 3 Expansion of different proportions of CD4-positive and CD8-positive T cells in human peripheral blood mononuclear cells (PBMC) (3)
[0054] In this example, PBMCs were freshly isolated from human whole blood by density centrifugation for activation and expansion of T cells. Transfer the separated PBMC cell suspension to the prepared 6-well culture dish, seeding density 1x10 6 / ml, use X-Vivo-15 (Lonza) medium 2mL / well added with lipid compound combination solution, and add CD3 antibody at a final concentration of 10μg / mL, CD28 antibody at a final concentration of 5μg / mL, and a final concentration of 100IU / mL IL2, and placed in a 37°C, 5% carbon dioxide incubator to continue culturing.
[0055] Wherein, the solute of the lipid compound combination solution is the following four kinds of lipids: oleic acid, palmitic acid, stearic fatty acid, and linolenic acid; the concentrations thereof are all 0.0001 g / L.
[0056] There are 9 conditions in the experiment, a...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com